New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: a case report

New-onset graves’ disease after the initiation of nivolumab therapy for gastric cancer: a case report

Abstract Background Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs) including thyroid dysfunction. There are only a few reports on Graves’ disease induced by ICIs. We report a case of new-onset Graves’ disease after the initiation of nivolumab therapy in a patien...

Full description

Bibliographic Details
Main Authors: Hiroshi Yamada, Fumitaka Okajima, Takeshi Onda, Shunji Fujimori, Naoya Emoto, Hitoshi Sugihara
Format: Article
Language:English
Published: BMC 2020-08-01
Series:BMC Endocrine Disorders
Subjects:
Graves’ disease
Nivolumab
Thyrotoxicosis
Immune checkpoint inhibitor
99mTc-pertechnetate scintigraphy
Thyroid-stimulating hormone receptor antibody
Online Access:http://link.springer.com/article/10.1186/s12902-020-00613-5

Internet

http://link.springer.com/article/10.1186/s12902-020-00613-5

Similar Items